FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324963198> ?p ?o ?g. }

• W2324963198 endingPage "467" @default.
• W2324963198 startingPage "463" @default.
• W2324963198 abstract "This double-blind, placebo controlled, multicentre, parallel trial assessed the efficacy of two oral doses of a new formulation of 5-aminosalicylic acid (5-ASA) targeted to release in the cecum which was given for six weeks to 136 patients with active ulcerative colitis. Seven centres participated (two Canadian, five American). Patients were randomly assigned to one of three treatment groups (4 g 5-ASA, 2 g 5-ASA or placebo). Medication was dispensed as 250 mg identically appearing tablets containing either 5-ASA or placebo to be taken four times a day. Subjects were assessed at baseline and after three and six weeks of treatment. Assessments included a disease activity index, physician's global assessment and flexible sigmoidoscopy. Compliance was assessed through pill count. A total of 136 patients participated ( 4 7 on 4 g 5-ASA, 45 on 2 g 5-ASA, and 44 on placebo). The three groups were similar in terms of age, weight, distribution of disease, extent of disease, and previous use of steroids or sulphasalazine. Ninety patients completed the six week study. Of the 46 dropouts, 38 (82.6%) left because of insufficient efficacy ( most on either place ho or 2 g 5-ASA), four (8.7%) had adverse reactions (all on 5-ASA), the remaining four (8.7%) left for reasons not related to their ulcerative colitis. The disease activity index represents a composite score ( maximum of 12) with categories for number of daily stools, presence of bleeding, abdominal pain and physician's assessment of disease activity. Patients who received 4 g 5-ASA daily demonstrated significant declines in disease activity index within three weeks of therapy and maintained improvement until the end of the stuuy. Although disease activity index declined for patients receiving 2 g 5-ASA daily, these changes did not reach statistical significance when compared to placebo-treated patients. On a five point scale (much improved, somewhat improved, unchanged, somewhat worse, much worse) the physician's global assessment mirrored the changes in disease activity index. Patients randomized to receive 4 g 5-ASA tablets were consistently noted as being either much or somewhat improved compared to placebo-treated patients. Side effects were few and minor and 52% (4 g 5-ASA), 42% (2 g 5-ASA) and 37% (placebo) of patients had no complaints. Headache was the most commonly cited adverse reaction for 6.9% (4 g 5-ASA) and 9.4% (2 g 5-ASA) of treated patients but 3.5% of placebo-treated patients also complained of headache. In conclusion in this randomized double-blind, placebo controlled study, patients with active ulcerative colitis randomized to 4 g 5-ASA per day noted improvement in disease activity as measured by disease activity index and physician's global assessment when compared to placebo-treated patients. ln contrast, patients who received 2 g 5-ASA daily did not demonstrate significant differences compared to the placebo group." @default.
• W2324963198 created "2016-06-24" @default.
• W2324963198 creator A5009549457 @default.
• W2324963198 creator A5013132324 @default.
• W2324963198 creator A5036484241 @default.
• W2324963198 creator A5042871525 @default.
• W2324963198 creator A5077963979 @default.
• W2324963198 creator A5079579508 @default.
• W2324963198 creator A5089728263 @default.
• W2324963198 date "1990-01-01" @default.
• W2324963198 modified "2023-10-16" @default.
• W2324963198 title "A Double-Blind, Placebo Controlled, Multicentre Study of the Efficacy And Safety of 5-Aminosalicylic Acid Tablets in the Treatment of Ulcerative Colitis" @default.
• W2324963198 doi "https://doi.org/10.1155/1990/921345" @default.
• W2324963198 hasPublicationYear "1990" @default.
• W2324963198 type Work @default.
• W2324963198 sameAs 2324963198 @default.
• W2324963198 citedByCount "37" @default.
• W2324963198 countsByYear W23249631982012 @default.
• W2324963198 countsByYear W23249631982013 @default.
• W2324963198 countsByYear W23249631982016 @default.
• W2324963198 countsByYear W23249631982017 @default.
• W2324963198 countsByYear W23249631982018 @default.
• W2324963198 countsByYear W23249631982019 @default.
• W2324963198 countsByYear W23249631982020 @default.
• W2324963198 crossrefType "journal-article" @default.
• W2324963198 hasAuthorship W2324963198A5009549457 @default.
• W2324963198 hasAuthorship W2324963198A5013132324 @default.
• W2324963198 hasAuthorship W2324963198A5036484241 @default.
• W2324963198 hasAuthorship W2324963198A5042871525 @default.
• W2324963198 hasAuthorship W2324963198A5077963979 @default.
• W2324963198 hasAuthorship W2324963198A5079579508 @default.
• W2324963198 hasAuthorship W2324963198A5089728263 @default.
• W2324963198 hasBestOaLocation W23249631981 @default.
• W2324963198 hasConcept C126322002 @default.
• W2324963198 hasConcept C141071460 @default.
• W2324963198 hasConcept C142724271 @default.
• W2324963198 hasConcept C197934379 @default.
• W2324963198 hasConcept C202061045 @default.
• W2324963198 hasConcept C204787440 @default.
• W2324963198 hasConcept C27081682 @default.
• W2324963198 hasConcept C2776206795 @default.
• W2324963198 hasConcept C2779134260 @default.
• W2324963198 hasConcept C2779174533 @default.
• W2324963198 hasConcept C2780479503 @default.
• W2324963198 hasConcept C2780955771 @default.
• W2324963198 hasConcept C2991744798 @default.
• W2324963198 hasConcept C71924100 @default.
• W2324963198 hasConcept C81603835 @default.
• W2324963198 hasConcept C90924648 @default.
• W2324963198 hasConcept C98274493 @default.
• W2324963198 hasConceptScore W2324963198C126322002 @default.
• W2324963198 hasConceptScore W2324963198C141071460 @default.
• W2324963198 hasConceptScore W2324963198C142724271 @default.
• W2324963198 hasConceptScore W2324963198C197934379 @default.
• W2324963198 hasConceptScore W2324963198C202061045 @default.
• W2324963198 hasConceptScore W2324963198C204787440 @default.
• W2324963198 hasConceptScore W2324963198C27081682 @default.
• W2324963198 hasConceptScore W2324963198C2776206795 @default.
• W2324963198 hasConceptScore W2324963198C2779134260 @default.
• W2324963198 hasConceptScore W2324963198C2779174533 @default.
• W2324963198 hasConceptScore W2324963198C2780479503 @default.
• W2324963198 hasConceptScore W2324963198C2780955771 @default.
• W2324963198 hasConceptScore W2324963198C2991744798 @default.
• W2324963198 hasConceptScore W2324963198C71924100 @default.
• W2324963198 hasConceptScore W2324963198C81603835 @default.
• W2324963198 hasConceptScore W2324963198C90924648 @default.
• W2324963198 hasConceptScore W2324963198C98274493 @default.
• W2324963198 hasIssue "7" @default.
• W2324963198 hasLocation W23249631981 @default.
• W2324963198 hasLocation W23249631982 @default.
• W2324963198 hasOpenAccess W2324963198 @default.
• W2324963198 hasPrimaryLocation W23249631981 @default.
• W2324963198 hasRelatedWork W1579473562 @default.
• W2324963198 hasRelatedWork W2021776982 @default.
• W2324963198 hasRelatedWork W2068252234 @default.
• W2324963198 hasRelatedWork W2078745520 @default.
• W2324963198 hasRelatedWork W2352254143 @default.
• W2324963198 hasRelatedWork W2376886101 @default.
• W2324963198 hasRelatedWork W2382465907 @default.
• W2324963198 hasRelatedWork W2386532431 @default.
• W2324963198 hasRelatedWork W2407927805 @default.
• W2324963198 hasRelatedWork W2409244310 @default.
• W2324963198 hasVolume "4" @default.
• W2324963198 isParatext "false" @default.
• W2324963198 isRetracted "false" @default.
• W2324963198 magId "2324963198" @default.
• W2324963198 workType "article" @default.